Atai Life Sciences Reports First Quarter 2024 Financial 💖 atai Life Sciences announces FDA Investigational New Drug

What date does atai Life Sciences's ATAI report Earnings

atai Life Sciences Reports Second Quarter 2024 Financial

Atai Life Sciences Q1 2024 Results Pipeline Update On DMT

Atai Life Sciences Reports Second Quarter 2024 Financial

atai Life Sciences Announces Positive Results From Phase 1

atai Life Sciences announces FDA Investigational New Drug

Atai Life Sciences Reports First Quarter 2024 Financial

atai Life Sciences to Announce FirstQuarter 2024 Financial

atai Life Sciences Unparalleled The Dales Report

Atai Cybin Give Positive Psychedelic Drug Study Updates

atai Life Sciences Announces Fourth Quarter and Full Year

atai Life Sciences on LinkedIn atai Life Sciences Reports

Atai Life Sciences ATAI Earnings Date and Reports 2024

atai Life Sciences Reports First Quarter 2024 Financial

Atai Life Sciences N Reports Second Quarter 2024 Financial


Il y a 3 jours · Earnings for Atai Life Sciences are expected to remain at ($0.69) per share in the coming year. Atai Life Sciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 22nd, 2024 based off prior year's report dates. Read More. 10 août 2024 · NEW YORK and BERLIN, Aug. 10, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health. 16 mai 2024 · Video interview with Management to be posted today at 8:30 a.m. EDT. NEW YORK and BERLIN, May 16, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage. 16 août 2024 · BERLIN and NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported its financial results for the second quarter ended June 30, 2024 and provided a corporate update. 8 janv. 2024 · UnitedHealth Group anticipates revenues between $357 billion and $360 billion, the mid-point of which indicates an improvement of 10.6% from the 2024 reported figure. It expects 2024 revenues. 17 mai 2024 · But before we dive in, atai Life Sciences delivered a plethora of positive business highlights which strengthened confidence that its business trajectory remains solidly intact. Foremost was the affirmation of a robust cash position, which at March 31, 2024 totaled $335 million and provides at least six quarters of operating runway through 2024. 24 mars 2024 · 241 0 Kommentare atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and In the fourth quarter of 2024, the first subject was dosed in a Phase 1 study of VLS-01. 11 mai 2024 · NEW YORK and BERLIN, May 11, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2024 financial results and provided corporate updates. 11 mai 2024 · atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and. 11 mai 2024 · ATAI LIFE SCIENCES N.V. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) March 31: December 31, 2024: 2024 (unaudited) (1) Assets: Cash and cash equivalents $ 185,885 $ 190,613: Securities carried at fair value: 63,998: 82,496: Prepaid expenses and other current assets: 9,199: 14,036: Short term notes receivable. 14 nov. 2024 · atai Life Sciences Reports Third Quarter 2024 Financial Results and Pipeline Highlights November 14, 2024 Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. 11 mai 2024 · ATAI LIFE SCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND ANNOUNCES PIPELINE HIGHLIGHTS AND UPDATES. $250M CASH POSITION AND COMMITTED TERM LOAN FUNDING IS EXPECTED TO FUND OPERATIONS INTO 1H 2026. QTRLY LOSS PER SHARE $0.21. Q1 EARNINGS PER SHARE VIEW $-0.21 — REFINITIV IBES DATA. 19 janv. 2024 · atai Life Sciences Reports First Quarter 2024 Financial Results and Announces Pipeline Highlights and Updates. NEW YORK and BERLIN, May 11, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorder. 2 oct. 2024 · atai Life Sciences Reports First Quarter 2024 Financial Results and Announces Pipeline Highlights and Updates. RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia. GRX-917: Presented PD. 22 mars 2024 · NEW YORK and BERLIN, March 06, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates. 2 oct. 2024 · atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates. atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates. READ ARTICLE. 2 oct. 2024 · atai Life Sciences Reports Second Quarter 2024 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) August 10, 2024 Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients. 6 mars 2024 · NEW YORK and BERLIN, March 06, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates. 6 mars 2024 · atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2024 financial results and provided corporate updates. “As the burden of unmet medical needs in mental health care continues to grow, our team remains highly. 24 mars 2024 · atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, atai is dedicated to acquiring, incubating, and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and. Register Today For A Free Demo Account To Practice. 77% Of Retail CFD Accounts Lose Money. With Advanced Educational And Trading Tools, Fortrade Is Undoubtedly The Platform For You. Our top 6 picks for the best forex brokers in 2024. Best Forex Broker Comparison 2024. The guideline to finding the best Forex brokers for forex trading. Pay Less on eToro™ with Zero-Commission Stock Trading. Start Now! Other fees may apply. Discuss Real-Time Market Trends with Top eToro™ Investors. Join Now! Other fees may apply. Il y a 2 jours · MT. Credit Suisse Lowers Atai Life Sciences' PT to $9 From $11, Updates Model After Announced Workforce Reduction; Keeps Outperform Rating. 23-03-07. MT. HC Wainwright Adjusts Price Target on Atai Life Sciences to $20 From $50, Maintains Buy Rating. 1.47M. 111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment. Il y a 3 jours · Atai Life Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, March 22nd, 2024 based off last year's report dates. Learn more on ATAI's earnings history. 18 janv. 2024 · Look out for ATAI's next earnings release expected on March 22, 2024. For the next earning release, we expect the company to report earnings of -$0.17 per share, reflecting a year-over-year. 10 août 2024 · ATAI LIFE SCIENCES N.V. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands) June 30: December 31, 2024 2024 (unaudited) (1) Assets: Cash and cash equivalents $ 141,090 $ 190,613: Securities carried at fair value: 86,402: 82,496: Prepaid expenses and other current assets: 6,257: 14,036: Short term notes receivable – related. 10 août 2024 · NEW YORK and BERLIN, Aug. 10, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2024 financial results and provided corporate updates. 19 janv. 2024 · atai Life Sciences Reports Second Quarter 2024 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) NEW YORK and BERLIN, Aug. 10, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform. 14 nov. 2024 · NEW YORK and BERLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2024 financial results and provided corporate updates. Learn how Planful can solve your toughest financial planning and reporting challenges. Built for speed, accuracy, and confidence. Month end reporting has never been so easy. 16 mai 2024 · atai ended the first quarter of 2024 with a cash position of $335 million which it anticipates will be sufficient to provide a cash runway through year end 2024. Cash, cash equivalents and short-term investments totaled $335 million as of March 31, 2024, compared to $362 million as of December 31, 2024. 4 mai 2024 · NEW YORK, May 04, 2024 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will announce its first-quarter 2024 financial results by posting them on the IR portion of its website. 17 mai 2024 · atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported financial results for the quarter ended March 31, 2024 and provided a business update. “We made great progress in the first. 4 mai 2024 · NEW YORK, May 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health. 16 août 2024 · Upcoming Milestones: Phase 2b trial results are expected in late 2024. Second Quarter 2024 Financial Results. Cash and Cash Equivalents. Cash and cash equivalents totaled $453.6 million as of June 30, 2024, compared to $97.2 million as of December 31, 2024. 16 août 2024 · Welcome to our second quarter 2024 ATAI Life Sciences financial results and corporate update conference call. The press release reporting our financial results is available in the. 15 nov. 2024 · atai Life Sciences Reports Third Quarter 2024 Financial Results and Corporate Update. -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4-. -Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase 2a and DemeRx’s Phase 1/2 trials as well as. 17 mai 2024 · atai Learns From Big Pharma’s Past Missteps To Improve Developed Drug Outcomes As noted in the outset, there are occasionally windows of insight during a company’s quarter-end conference call that provide clarity on the operating philosophies of a company. 25 mai 2024 · By Benjamin A. Smith On May 25, 2024. In the speculative world of ‘psychedelic’ biotech, companies that are under-capitalized or lacking pipeline diversity face an uphill battle to reach the finish line. However, such complexities are not a concern for atai Life Sciences N.V. (NASDAQ: ATAI), as the company boasts a robust. 22 août 2024 · When atai Life Sciences (NASDAQ: ATAI) filed its Form S-1 back on April 20, 2024, the company became best known for its associations with atai Life Sciences. 12 janv. 2024 · atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the U.S. Food and Drug Administration (FDA) has given Investigational New Drug (IND) clearance to conduct a clinical DDI study of PCN-101 (R-ketamine). atai plans to initiate the study e. 27 janv. 2024 · Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs).